Loading, Please Wait...
CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the selection of new research for presentation at the AACR Annual Meeting, being held March 29 – April 3, 2019 in Atlanta, GA. This research demonstrates the potential of our Fc multimerization technology to significantly enhance the potency and efficacy of a variety of cell depleting therapeutic antibodies, including antibodies targeting CD38 and CTLA-4.
“Therapeutics like Rituxan® and Darzalex®, which engage the Fc gamma receptor and complement systems to mediate cell depletion, are important standards-of-care for patients with cancer and autoimmune disease. However, inefficent engagement limits efficacy and, in many patients, contributes to drug resistance,” said Tony Manning, Ph.D., Momenta’s chief scientific officer. “Importantly, these posters featured at AACR demonstrate the potential of Momenta’s Fc multimerization technology to maximize engagement of the Fc gamma receptor and complement system, thereby enabling the discovery of potentially best-in-class agents targeting CD38 and CTLA-4. Further, this research reinforces our belief in the broad applicability of our Fc multimerization platform to produce enhanced therapeutic antibodies across a range of targets, including for the treatment of cancer.”
Title: Discovery of a Potential Best-in-Class Anti-CD38 Therapeutic Utilizing Fc Multimerization(Session PO.IM02.16 – Therapeutic Antibodies 1, Abstract 561/25)
Date: March 31, 2019
Time: 1:00 pm-5:00 pm ET
Location: Section 23, Georgia World Conference Center, Atlanta
Anti-CD38 monoclonal antibodies (mAbs) induce tumor cell depletion in part by Fc-dependent effector mechanisms. This presentation describes the discovery of a novel anti-CD38 Fc multimer with superior efficacy and potency to existing anti-CD38 therapeutic antibodies in both cell systems and in non-human primates, and also with the ability to efficiently deplete Darzalex-resistant multiple myeloma patient tumor cells.
Title: Improved Fc-mediated Effector Functions By An Anti-CTLA-4 Multivalent Fc Agent
(Session PO.IM02.05 – Immune Checkpoints 1, Abstract 3244 / 24)
Date: April 2, 2019
Time: 8:00 am -12:00 pm ET
Location: Section 24, Georgia World Conference Center, Atlanta
This presentation describes the discovery of a novel anti-CTLA-4 Fc multimer that maintains checkpoint blockade activity whilst simultaneously enhancing the ability to deplete CTLA-4-expressing T regulatory cells with immune-supressive activity. Such an agent has potential to enhance anti-tumor activity through the dual mechanisms of checkpoint blockade and Treg depletion.
Materials from both sessions will be available for download following their formal presentation at: Momenta Events and Presentations
Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Momenta’s product candidate, M281, is a potentially best-in-class anti-FcRn antibody; M254, is a hypersialylated human immunoglobulin (hsIgG) designed as a high potency alternative to intravenous immunoglobulin (IVIg); and M230 (CSL730), is a potential first-in-class novel recombinant Fc multimer being developed in collaboration with CSL. Momenta also has a focused pipeline of two biosimilar candidates: M923, Momenta’s wholly-owned proposed biosimilar to HUMIRA®, and M710, a proposed biosimilar to EYLEA® being developed in collaboration with Mylan. Momenta’s two FDA-approved complex generic products, enoxaparin sodium injection and Glatopa® (glatiramer acetate injection), are marketed by its collaboration partner, Sandoz.
To learn more about Momenta, please visit www.momentapharma.com, which does not form a part of this press release.
Momenta’s logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the design, timing and goals of clinical trials, and the availability and timing of reporting results; the use efficacy, safety, tolerability, convenience and commercial potential of our product candidates, including their potential as best-in-class agents and the potential actions and effects of our product candidates. Forward-looking statements may be identified by words such as "believe," "continue," “plan to”, "potential," "will," and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including the risk of the unpredictable nature of early stage development efforts for our product candidates; safety, efficacy or tolerability problems with our product candidates; unexpected adverse clinical trial results; and those referred to under the section "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.